Saturday 17 October 2026
Export ACHV’s income statement to Excel — free account
Achieve Life Sciences, Inc.
ACHV Healthcare Biotechnology
In the quarter to June 2026, EPS fell 116.2%, free cash flow fell 19.0% and total debt rose 63.9%, each against the same quarter a year earlier.
6.38
0.59
−8.46%
Follow ACHV
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(161.08%) | (257.67%) | (496.15%) | (844.99%) | |
| (104.74%) | (135.90%) | (171.97%) | (91.46%) | ||
ROIC |
0.00% | (2,109.47%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(129.81%) | (177.39%) | (270.38%) | 1,217.99% | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.80) | (1.14) | (0.85) | (0.50) | |
Free Cash Flow |
(40.68) | (49.49) | (45.31) | (47.06) | |
Capital Expenditures |
— | (0.02) | — | (0.04) | |
| Other line items | |||||
Cash ROIC |
(44.37%) | (66.49%) | (82.53%) | (24.91%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
(68.42) | (67.01) | (57.76) | (58.63) | |
Operating CF/Net income |
0.78 | 0.91 | 0.87 | 0.41 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
0.00 | (0.09) | 0.00 | (0.14) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.80) | (1.13) | (0.85) | (0.50) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | — | 0.00 |
Columns are period end dates